Recruiting

Managing heart health in prostate cancer patients on hormone therapy

Plain-English translation of NCT06202820 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Read our Prostate Cancer research guide →

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new care program designed to help prostate cancer patients who are starting androgen deprivation therapy (ADT)—a hormone-blocking treatment—stay heart-healthy during their cancer treatment. The program includes education, monitoring, and management of heart health risks. Researchers want to create a standardized approach that can be used for all prostate cancer patients receiving this type of therapy.

Hormone-blocking therapy for prostate cancer can sometimes increase heart disease risk. This trial exists to create a structured program that catches and manages these risks early, so patients can benefit from their cancer treatment without unnecessary heart complications.

Do you qualify?

You likely qualify if…

you have been diagnosed with prostate cancer and your doctor has recommended at least 24 weeks of hormone-blocking therapy
you have received no more than 12 weeks of hormone-blocking therapy so far
you are willing to attend follow-up visits at Dana-Farber Cancer Institute's Longwood location at weeks 4, 12, and 24
you are willing to have blood work and blood pressure checks, either in person or at home for virtual visits
you are at least 18 years old with a life expectancy of more than 6 months
you can understand and sign an informed consent form

You likely don't qualify if…

you have had a heart attack, new or worsening heart failure, or stroke in the past 6 months
you have already been receiving hormone-blocking therapy for more than 12 weeks
you are also receiving chemotherapy or radioactive therapy for your prostate cancer
you are currently enrolled in another clinical trial that would limit your time commitment
your cancer treatment plan requires intensive symptom management that would conflict with this program

What participation looks like

You would receive your standard prostate cancer hormone therapy and attend clinic visits at weeks 4, 12, and 24. At these visits, you'll complete heart health education modules, answer surveys about your health, have blood work and blood pressure checks, and share feedback about the program. The whole study lasts about 6 months, and your input will help improve the program for future patients.

AI-generated summary from trial data · Jul 8, 2026 · Not medical advice

Trial locations(2 sites)

United States

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts